ARS Pharma reports Q2 net loss $17.4M; neffy PDUFA date Sept 19, 2023

ARS Pharmaceuticals, Inc.

Cash, equivalents and short-term investments $252.2M as of June 30, 2023, funding at least three years.
R&D expense $7.3M, G&A $13.3M, net loss $17.4M for Q2 2023.
PDUFA target action date for neffy NDA (intranasal epinephrine) set for September 19, 2023.
FDA Advisory Committee voted 16:6 adults, 17:5 children for favorable benefit-risk profile.
Commercial preparations underway; hiring 115 field reps; European MAA decision expected by year end 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARS Pharmaceuticals, Inc. reported the three and six months ended June 30, 2023 results: net income Net loss was $17.4 million for the quarter ended June 30, 2023..

Period: the three and six months ended June 30, 2023
Net income: Net loss was $17.4 million for the quarter ended June 30, 2023.
Result: reported results

Exact text from the filing

On August 10, 2023, ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

ARS Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.